Association between PCSK9 targeted therapy and the risk of stroke and dementia: A Meta-Analysis of Randomized Controlled Trials.
BACKGROUND Proprotein convertase subtilisin/kexin type 9 (PCSK9) targeted therapies have been shown to reduce low-density lipoprotein cholesterol (LDL-C) levels and circulating PCSK9. However, its effect on cerebrovascular outcomes, especially stroke and dementia, has not been well established to date. METHODS We con...